Silo Pharma Highlights Federal Momentum in Psychedelic Therapeutics Development
April 29th, 2026 3:04 PM
By: Newsworthy Staff
Silo Pharma Inc. notes that coordinated U.S. federal actions, including funding and regulatory advancements, are accelerating the development of psychedelic-based therapies for mental health and substance use disorders.
Silo Pharma Inc. (NASDAQ: SILO) has commented on a series of coordinated U.S. federal actions that are accelerating the development of psychedelic-based therapies for mental health and substance use disorders. The company cited new funding initiatives, clinical progress, and regulatory advancements as signals of growing institutional support and increased clarity that are expected to drive innovation in treating conditions such as PTSD and addiction.
Among the developments highlighted by Silo Pharma are programs from agencies including the Advanced Research Projects Agency for Health (ARPA-H) and the U.S. Food and Drug Administration (FDA). The company pointed to the FDA's clearance of an Investigational New Drug (IND) application for a noribogaine candidate and the issuance of priority review vouchers to leading organizations as examples of the federal government's commitment to advancing psychedelic therapeutics.
"We are encouraged by the momentum we are seeing at the federal level," said a representative from Silo Pharma. "These actions underscore the growing recognition of the potential of psychedelic-based therapies to address unmet medical needs in mental health and addiction."
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
The full press release is available at https://ibn.fm/TpB23. For more information about Silo Pharma, visit silopharma.com.
The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
